AcquisitionOther
Fulcrum Therapeutics, Inc. acquired target
Public M&A record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Fulcrum Therapeutics, Inc. -> target · $245 million
(“Slate”), a biotechnology company developing next-generation therapeutics for the treatment of migraine, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction (the “Merger”).
Open source record (SEC) ↗